Acucela Announces Presentation of Data in Preclinical Study of Retinopathy.BOTHELL, Wash. -- Acucela Inc., a clinical-stage biotechnology company discovering new drug therapies for eye diseases, today announced that data from a preclinical study in retinopathy of prematurity retinopathy of prematurity n. Abnormal replacement of the sensory retina by fibrous tissue and blood vessels, occurring mainly in premature infants who are placed in a high-oxygen environment. (ROP (1) (Raster Operation) An instruction that manipulates the bits of a bitmapped image in some manner. (2) (RISC Operation) An instruction in a RISC processor. ) will be presented at the Association for Research in Vision and Ophthalmology (ARVO ARVO Association for Research in Vision and Ophthalmology. ) Annual Meeting being held April 27 through May 1 in Fort Lauderdale, Florida Fort Lauderdale, known as the "Venice of America" due to its expansive and intricate canal system, is a city in Broward County, Florida, United States. The city's population is described as metropolitan, where diverse culture is commonplace. According to 2006 U.S. . The data will be presented by researchers from Children's Hospital Boston Children's Hospital Boston is a children's hospital located in the Longwood Medical and Academic Area of Boston, Massachusetts. Located at 300 Longwood Avenue, Children's is adjacent both to its teaching affiliate, Harvard Medical School, and to Dana-Farber Cancer Institute. . Presentation Details: * Date and Time: April 29, 2008, 8:30 a.m. - 10:15 a.m. EDT * Retinal Cell Biology Session: Retinal and Choroidal cho·roi·dal adj. Of or relating to the choroid. choroidal pertaining to or emanating from the choroid. choroidal hypoplasia Angiogenesis II, Hall B/C * Abstract Number: 2629 / A354 * Poster Presentation: Effects of a Vitamin-A Derivative (AG-787-14-2) on Retinal Function in Oxygen-Induced Retinopathy * Presenter: James D. Akula, Ph.D. About Visual Cycle Modulation and its Impact on Blinding Eye Diseases Visual cycle modulation may have the ability to impact multiple blinding eye diseases. Acucela is developing an orally available drug that inhibits the visual cycle potentially impacting the processes that can lead to blinding eye diseases such as age-related macular degeneration Age-related macular degeneration (ARMD) Degeneration of the macula (the central part of the retina where the rods and cones are most dense) that leads to loss of central vision in people over 60. (AMD), diabetic retinopathy, retinopathy of prematurity and Stargardt disease. About Acucela Acucela Inc. is focused on developing new drug therapies for eye diseases, and particularly neurodegenerative retinal diseases such as macular degeneration. The company has proprietary disease-specific assays and technologies to identify and develop compounds that may safely and effectively treat retinal diseases and injuries. The company's novel approaches have significant therapeutic potential to treat retinal diseases such as Age-related Macular Degeneration (AMD) and Stargardt disease, which affect 50 million people worldwide. The Bothell-based, privately-held, biotechnology company was founded in 2002. For more information, please visit http://www.acucela.com. Forward-Looking Statement This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Acucela undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion